# CRISPR Brief — Sample Issue
**Functional Genomics Intelligence** | Sample Issue Zero (not yet published)
*Author: E. Voss — former industry research scientist*

---

## Issue Metadata

| Field | Value |
|-------|-------|
| **Issue** | Zero (sample — not yet published) |
| **Date** | April 2026 |
| **Cadence** | Biweekly — every other Thursday |
| **Sections** | bioRxiv Watch · FDA Filing Tracker · Pipeline Mover · Meta |
| **Price** | $10/mo early-bird (locked for life) · $12/mo after launch |

---

## Section 1 — bioRxiv Watch

### Paper: "Prime editing achieves therapeutic hemoglobin F reactivation in sickle cell disease"
**bioRxiv DOI:** 10.1101/2026.04.XX.XXXXX (preprint, not peer-reviewed)
**Impact Score: 8.4 / 10**
**TL;DR:** Prime editors targeted HBG promoters in hematopoietic stem cells and achieved 89% HbF reactivation in a mouse model, with no detectable off-target edits at top 50 predicted sites. This is the first prime editing approach to match the editing efficiency of base editors in this indication — and with a better safety profile.

**Why this matters for scouts and VCs:**

Sickle cell disease has become a crowded gene therapy space: Vertex/CRISPR's Casgevy (exagamglogene autotemcel) is approved, Bluebird Bio's lovo-cel is in BLA review, and at least 6 base editor programs are active. The competitive moat in this space is shifting from "can we edit?" to "can we edit without genotoxicity?"

Prime editing's advantage here is precision: it writes the exact HbF-correcting edit (a T→A at HBG -200) without creating double-strand breaks. The paper shows no detectable large deletions or chromosomal rearrangements — the failure mode that killed at least one earlier base editor program. For a scout evaluating gene therapy companies, this paper suggests prime editing may close the safety gap that currently limits base editor programs in hemoglobinopathies.

**Key datapoint for pipeline tracking:** 89% HbF reactivation in vivo. For reference, Casgevy's Phase 3 showed ~80% HbF reactivation in treated patients at 12 months. This is a comparable efficacy signal with a potentially superior safety profile in a preclinical model.

**One concern:** Mouse model only. Translation to human HSCs and subsequent engraftment remains untested. The paper does not report long-term engraftment durability beyond 16 weeks.

---

## Section 2 — FDA Filing Tracker

### Filing: Verve Therapeutics — VERVE-101 (IND application)
**Indication:** Heterozygous familial hypercholesterolemia (HeFH)
**Event:** IND clearance (April 2026)
**Status:** Proceed to Phase 1b

**What this means:**

VERVE-101 is an in vivo base editing program that targets PCSK9 in the liver — one shot, permanent knock-down. This is not a cell therapy; it's a systemic infusion that delivers mRNA-encoded base editors directly to hepatocytes. The IND clearance means VERVE can now begin dosing in human subjects.

This is significant because the PCSK9 space is about to get crowded. Two siRNA drugs (inclisiran) are approved and a third (olpasiran) is in Phase 3. An in vivo base editor that claims durable PCSK9 knock-down after a single dose would be competitively differentiated if the Phase 1 safety profile holds. For scouts tracking the cardiovascular gene therapy space, this IND is a key milestone — the first in vivo base editor to enter the clinic for a cardiometabolic indication.

**What to watch:** Phase 1b dose-escalation data (expected H2 2026). Primary endpoints: safety and tolerability. Secondary: LDL-C reduction at 6 months.

---

## Section 3 — Pipeline Mover

### Company: Beam Therapeutics — Base editing platform update
**Event:** Manufacturing partnership with National Institutes of Health (NIH) for GMP-grade base editor manufacturing
**Strategic relevance:** High

Beam's core challenge has been manufacturing scale: manufacturing CRISPR base editors to GMP standards for in vivo delivery is harder than for ex vivo cell therapies. The NIH partnership signals that Beam has a viable path to clinical-grade supply and is no longer solely dependent on its own manufacturing infrastructure.

This does not change Beam's competitive position in the near term, but it removes a key diligence question that VCs have been raising: "Can they actually manufacture at scale?" The answer, as of this partnership, is: partially, with NIH support.

---

## Section 4 — Meta

**Issue cadence:** Biweekly — every other Thursday.
**This issue's sources:** 1 bioRxiv preprint, 1 FDA filing event, 1 company pipeline update.
**Next issue:** May 7, 2026 (bioRxiv Watch + FDA tracker + pipeline mover).

**What makes CRISPR Brief different:**
Most biotech newsletters either dump abstracts (too much noise) or give you a one-paragraph summary (too little signal). CRISPR Brief gives you the scientist's reading: what the paper actually found, what it means for the competitive landscape, and what to track next. No sponsored content. No opinions. Just sourced, citable analysis.

**Pricing:** Free for first 200 subscribers. $10/month after (early-bird rate — locked for life).
**Subscribe at:** https://store-v2-khaki.vercel.app/crispr-brief.html

---

*CRISPR Brief is written by a former industry research scientist. Analysis is based on publicly available data. This issue is a sample — not investment advice.*